scholarly journals Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in Intubated Patients: Case Series and Literature Review

2018 ◽  
Vol 2018 ◽  
pp. 1-6
Author(s):  
Erin K. Yeung ◽  
Haritha Saikumar ◽  
Jose Castaneda-Nerio ◽  
Sandra G. Adams ◽  
Mark Wong
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Literature Review ◽  
Angiotensin Converting Enzyme ◽  
Angiotensin Converting Enzyme Inhibitor ◽  
Enzyme Inhibitor ◽  
Case Reports ◽  
Case Series ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitor

Purpose. A case series of icatibant use in intubated patients with angiotensin-converting enzyme inhibitor- (ACEI-) induced angioedema is presented along with a relevant literature review and recommendations for utilization. Summary. Three intubated patients admitted to the intensive care unit for ACEI-induced angioedema were treated with icatibant. A literature search identified one controlled study and four case reports describing the use of icatibant in intubated ACEI-induced angioedema patients. Conclusion. Icatibant administration in intubated patients may be beneficial in decreasing time to extubation and length of intensive care unit stay. In the three cases described, icatibant administration did not appear to elicit a response in intubated patients, which has been described in previous case reports. For clinicians considering icatibant in the treatment of ACEI-induced angioedema, earlier administration upon arrival to the ED or immediately upon arriving to the intensive care unit is strongly advised. The suggested benefit of icatibant in intubated ACEI-induced angioedema patients should be verified by randomized clinical trials and cost-benefit analyses should be performed at individual institutions.

scholarly journals Pengaruh penggunaan angiotensin converting enzyme inhibitor (ACEI) dan angiotensin receptor blocker (ARB) pada pasien coronavirus disease 2019 (covid-19) dengan hipertensi

e-CliniC ◽  
2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Briando Linelejan ◽  
Octavianus Umboh ◽  
Frans E. N. Wantania
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Literature Review ◽  
Angiotensin Converting Enzyme ◽  
Angiotensin Converting Enzyme Inhibitor ◽  
Enzyme Inhibitor ◽  
Angiotensin Receptor Blockers ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitor ◽  
Receptor Blockers

Abstract: Hypertension is considered as one of the highest death-caused disease worldwide. Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) most frequently occurred in elderly and those who had comorbid diseases, one of them is hypertension. The first line drugs that are usually used in hypertension are angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). It is assumed that these drugs coud influence the progress of COVID-19 due to the similiar target receptor. This study was aimed to evaluate the influence of ACEIs and ARBs to patients with COVID-19 and hypertension. This was a literature review study using literatures published in medical journal databases such as PubMed and ClinicalKey. The results obtained 10 literatures that fulfilled the inclusion and exclusion criteria. These ten literatures stated that there was no influence of using ACEIs and ARBs in COVID-19 patients. In conclusion, ACEIs and ARBs do not influence the mortality or progresivity of COVID-19 disease and are suggested to be consumed continually.Keywords: ACEIs, ARBs, COVID-19, hypertension, hypertension in COVID-19 Abstrak: Hipertensi merupakan salah satu penyebab kematian tertinggi di dunia. Pandemik coronavirus disease 2019 (COVID-19) dengan severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sebagai etiologinya kebanyakan terjadi pada usia tua serta yang memiliki penyakit komorbid, salah satu yang tersering ialah hipertensi. Obat lini pertama yang biasa digunakan untuk hipertensi yaitu angiotensin converting enzyme inhibitor (ACEI) dan angiotensin receptor blockers (ARB) dikatakan dapat memengaruhi perkembangan penyakit COVID-19 karena memiliki reseptor atau tempat kerja yang mirip. Penelitian ini bertujuan untuk mengevaluasi pengaruh penggunaan ACEI dan ARB pada pasien COVID-19 dengan hipertensi. Jenis penelitian ialah literature review dengan menggunakan literatur-literatur yang dipublikasi dalam database jurnal kedokteran PubMed dan ClinicalKey sesuai dengan kriteria inklusi dan eksklusi penelitian. Hasil penelitian mendapatkan 10 literatur; kesemuanya menyatakan bahwa tidak terdapat pengaruh penggunaan ACEI dan ARB terhadap pasien COVID-19. Simpulan penelitian ini penggunaan ACEI dan ARB tidak memengaruhi mortalitas maupun progresivitas penyakit COVID-19 dan disarankan untuk tetap dilanjutkan.Kata kunci: ACEI, ARB, COVID-19, hipertensi, hipertensi pada COVID-19

Sign in / Sign up

Export Citation Format

Share Document